Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate plus gefitinib in EGFR-mutant advanced NSCLC
ChiCTR-IIR-16007908Phase 2Recruiting
- Sponsor
- Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Gefitinib + zoledronate with Gefitinib + placebo (2 arms). Primary endpoint: Progression-free survival. Started Feb 2016; status: recruiting.
02
Drugs
zoledronategefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-16007908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16007908.